Capabilities

Merger with Endologix, Inc.

Trivascular Technologies, Inc.
2015 - 2016

Our attorneys represented TriVascular Technologies, Inc., a publicly-traded medical device company, in its merger with Endologix, Inc., a publicly-traded developer and manufacturer of minimally invasive treatments for aortic disorders. In this transaction, which closed in February 2016, TriVascular stockholders received approximately 19.9% of Endologix outstanding common stock and certain cash payments, resulting in approximately 16% ownership of the combined company.  

Email Disclaimer